VISIONARY: Sibeprenlimab in IgA nephropathy #IgAN ✅ Proteinuria reduction ✅ Preservation of kidney function #Nephpearls #GlomConHawaii 🌊 #NephSky #VisualAbstract by @alexgr23.bsky.social

nsMRAs in CKM Syndrome: Disease-Specific Deep Dives www.medscape.org/viewarticle/... via @MedscapeCME #Nephpearls #NephSky

Targeting BAFF and APRIL in IgA Nephropathy reachmd.com/programs/fro... via @ReachMD #Nephpearls #NephSky

Targeting BAFF and APRIL in IgA Nephropathy

Advances in our understanding of BAFF and APRIL biology are reshaping the treatment landscape for IgA nephropathy (IgAN), with dual pathway inhibition emerging as a promising disease-modifying strateg...

reachmd.com

Save the date #WCN27 🇲🇾 #ISNWCN 🇲🇾 #NephSky

Urea vs. tolvaptan for hospitalized patients with SIADH ca. 2026 #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/42455009/

Kick, Sweat, Protect: Kidney Health Through the Lens of Soccer (Football) ca. 2026 #Nephpearls #WorldCup #WorldCup2026 #NephSky 👉🏼 www.kidneymedicinejournal.org/article/S259...

Enthusiasm for EGDT has waned as 3 large, multicenter trials failed to reproduce the results of the Rivers trial #Nephpearls #AKIinICU #NephSky 🔑 Current Surviving Sepsis guidelines recommend an initial bolus of 30 mL/kg to be followed by additional fluid to maintain and improve perfusion

Obesity in CKD: Treatment algorithm ca. 2026 from @ndt-era.bsky.social @saynanorouzi.bsky.social @rahaai.bsky.social #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42446420/

The kidney in the middle: @kdigo.org guidelines address multiple key components of cardiovascular-kidney-metabolic syndrome ca. 2026 from @Kidney_Int #Nephpearls #Cardiorenal #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/42191113/

When shock is refractory to initial fluid resuscitation, it is appropriate to consider vasopressor support #Nephpearls #AKIinICU #NephSky 📌 Distributive shock requires alpha-adrenergic stimulation to promote vasoconstriction and raise SVR

Screening algorithms in septic shock #Nephpearls #AKIinICU #NephSky ⚠️ SIRS may be highly sensitive but lacks specificity ⚠️ qSOFA may lack sensitivity for early sepsis or septic shock 🔑 These limitations highlight the importance of high clinical suspicion for shock 👉 shop.lww.com/Handbook-of-...

The fundamental problem in shock is "inadequate end-organ perfusion" #Nephpearls #AKIinICU #NephSky 📌 Low cardiac output (CO) ✔️ Hypovolemic ✔️ Cardiogenic ✔️ Obstructive 📌 Low systemic vascular resistance (SVR) aka Distributive: Sepsis

The Role of APRIL and the 4-Hit Process in the Pathogenesis of IgA Nephropathy #Nephpearls #NephSky reachmd.com/programs/med...

The Role of APRIL and the 4-Hit Process in the Pathogenesis of IgA Nephropathy

To understand the pathogenesis of IgA nephropathy (IgAN), it’s important to look at the immune processes driving damage caused by the disease. The 4-hit process shows why and how IgAN progresses on th...

reachmd.com

B cell maturation, treatment targets, and therapies ca. 2026 from @kidneyint.bsky.social @kdigo.org #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42034308/

Fabry Disease: Current Perspectives on Diagnosis and Management Strategies ca. 2026 from @akdhjournal.bsky.social @saynanorouzi.bsky.social #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/42331443/

ARISE FLUIDS: Vasopressors or Fluids in Early Septic Shock ca. 2026 from @nejm.org #Nephpearls #AKIinICU #NephSky 📌 No significant difference in days alive and out of hospital at day 90 ⚠️ Pulmonary edema: Lower in restricted fluids group (0.6% vs. 5.0%) 👉 pubmed.ncbi.nlm.nih.gov/42274006/

Guideline for Prevention, Detection, Evaluation, & Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome ca. 2026 from @americanheart.bsky.social @accintouch.bsky.social @amdiabetesassn.bsky.social @asnkidney.bsky.social #Nephpearls #Cardiorenal #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42265997/

C3 glomerulopathy in transplant “like yet unlike native”: Pathophysiology, recent advances in therapeutics and evolving paradigms ca. 2026 @saynanorouzi.bsky.social #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42281853/

Mechanisms by which novel antihypertensive drug classes reduce blood pressure ca. 2025 from @natrevcardiol.nature.com #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/39920248/

Aprocitentan in Patients With CKD and Resistant Hypertension ca. 2026 #Nephpearls #NephSky ✅ Well tolerated ✅ Lowered BP (nighttime ambulatory BP) ✅ Markedly reduced urine albumin-to-creatinine ratio (UACR) in participants w/ CKD and resistant hypertension 👉 pubmed.ncbi.nlm.nih.gov/41363010/

Hemodynamic monitoring in in ICU: Capillary refill time (CRT), is quick, easily performed, and a long-standing component of the physical exam #Nephpearls #AKIinICU #NephSky 👉 pubmed.ncbi.nlm.nih.gov/30772908/ 👉 www.wolterskluwer.com/en/solutions...

FIND-CKD: Among adults with CKD who did not have diabetes, finerenone led to a slower decrease in the eGFR than placebo over 32 months ca. 2026 from @nejm.org #Nephpearls #ERA26 #NephSky 👉 www.nejm.org/doi/full/10....

Hyperkalemia and Its Treatment: Real-World Evidence and Managed Care Considerations Supporting Use of Potassium Binders ca. 2026 from @beaverspharmd.bsky.social #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42213908/

Consensus Recommendation: Real World Insights on Attitudes and Treatment of Hyperkalemia ca. 2026 from @garysinger.bsky.social @renalphysicians.bsky.social #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42069178/

Treatment of chronic hyponatremia from Dr Ewout Hoorn #Nephpearls #ERA26 #NephSky

Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial ca. 2026 from @asnpublications.bsky.social #Nephpearls #ERA26 #NephSky 👉 pubmed.ncbi.nlm.nih.gov/40913594/

Ultrafiltration and Sodium Removal in Steady Concentration Peritoneal Dialysis: A Prospective, Multicenter, Randomized, Crossover Study ca. 2026 from @asnpublications.bsky.social @wilkiemart.bsky.social #Nephpearls #ERA26 #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42240452/

C3 glomerulopathy in transplant “like yet unlike native”: Pathophysiology, recent advances in therapeutics and evolving paradigms ca. 2026 @saynanorouzi.bsky.social #Nephpearls #NephSky 👉 www.wjgnet.com/2220-3230/fu...

SAVE THE DATE for upcoming #ECNeph "Nephrotic syndrome in a patient with diabetes" 🗓️ 28th May, Thursday ⏰ 8PM IST 🇮🇳, 1030AM EST 🇺🇸, 1030PM PHT 🇵🇭 #Nephpearls #NerphSky

Glomerular frontiers: consensus perspectives from @glomcon.org @n0r0zha.bsky.social @poyanmehr.org @bettercallseeth.bsky.social @saynanorouzi.bsky.social #GlomconHawaii 🌊 2025 #NephSky #Nephpearls 👉 link.springer.com/article/10.1...